{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T18:13:19Z","timestamp":1764785599333,"version":"3.40.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100014382","name":"Ipsen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s12325-025-03126-6","type":"journal-article","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T08:11:06Z","timestamp":1741853466000},"page":"2190-2218","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Burden of Comorbidities and Concomitant Medications and Their Associated Costs in Patients with Gastroenteropancreatic or Lung Neuroendocrine Tumors: Analysis of US Administrative Data"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2523-9598","authenticated-orcid":false,"given":"Jennifer A.","family":"Chan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"Antonio","family":"Ribeiro-Oliveira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aude","family":"Houchard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syvart","family":"Dennen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sai Sriteja Boppudi","family":"Naga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yajin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christelle","family":"Pommie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timon","family":"Vandamme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Starr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,13]]},"reference":[{"issue":"7","key":"3126_CR1","doi-asserted-by":"publisher","first-page":"839","DOI":"10.6004\/jnccn.2021.0032","volume":"19","author":"MH Shah","year":"2021","unstructured":"Shah MH, Goldner WS, Benson AB, et al. Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(7):839\u201368.","journal-title":"J Natl Compr Canc Netw"},{"issue":"10","key":"3126_CR2","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","volume":"3","author":"A Dasari","year":"2017","unstructured":"Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335\u201342.","journal-title":"JAMA Oncol"},{"issue":"5","key":"3126_CR3","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1097\/CEJ.0000000000000877","volume":"33","author":"Y Zhu","year":"2024","unstructured":"Zhu Y. Incidence trend of neuroendocrine tumors and disparities by sex and race\/ethnicity in adults from the United States, 2000\u20132020. Eur J Cancer Prev. 2024;33(5):475\u201384.","journal-title":"Eur J Cancer Prev"},{"issue":"12","key":"3126_CR4","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.neo.2017.09.002","volume":"19","author":"B Oronsky","year":"2017","unstructured":"Oronsky B, Ma PC, Morgensztern D, Carter CA. Nothing but NET: a review of neuroendocrine tumors and carcinomas. Neoplasia. 2017;19(12):991\u20131002.","journal-title":"Neoplasia"},{"issue":"3","key":"3126_CR5","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1210\/endrev\/bnad035","volume":"45","author":"MCF Mulders","year":"2023","unstructured":"Mulders MCF, de Herder WW, Hofland J. What is carcinoid syndrome? A critical appraisal of its proposed mediators. Endocr Rev. 2023;45(3):351\u201360.","journal-title":"Endocr Rev"},{"issue":"4","key":"3126_CR6","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S1470-2045(17)30110-9","volume":"18","author":"DM Halperin","year":"2017","unstructured":"Halperin DM, Shen C, Dasari A, et al. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. Lancet Oncol. 2017;18(4):525\u201334.","journal-title":"Lancet Oncol"},{"issue":"7","key":"3126_CR7","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-22-0226","volume":"30","author":"J Del Rivero","year":"2023","unstructured":"Del Rivero J, Mailman J, Rabow MW, et al. Practical considerations when providing palliative care to patients with neuroendocrine tumors in the context of routine disease management or hospice care. Endocr Relat Cancer. 2023;30(7):e220226.","journal-title":"Endocr Relat Cancer"},{"issue":"7","key":"3126_CR8","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.3390\/jcm9072203","volume":"9","author":"MI Del Olmo-Garc\u00eda","year":"2020","unstructured":"Del Olmo-Garc\u00eda MI, Muros MA, L\u00f3pez-de-la-Torre M, et al. Prevention and management of hormonal crisis during theragnosis with LU-DOTA-TATE in neuroendocrine tumors. A systematic review and approach proposal. J Clin Med. 2020;9(7):2203.","journal-title":"J Clin Med"},{"issue":"12","key":"3126_CR9","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.2217\/fon-2017-0340","volume":"14","author":"JS Dillon","year":"2018","unstructured":"Dillon JS, Chandrasekharan C. Telotristat ethyl: a novel agent for the therapy of carcinoid syndrome diarrhea. Future Oncol. 2018;14(12):1155\u201364.","journal-title":"Future Oncol"},{"issue":"7","key":"3126_CR10","doi-asserted-by":"publisher","first-page":"e1171","DOI":"10.1002\/onco.13847","volume":"26","author":"LB Anthony","year":"2021","unstructured":"Anthony LB, O\u2019Dorisio TM. Opportunities to improve symptom control with somatostatin congeners in GEP-NETs: a review of key issues. Oncologist. 2021;26(7):e1171\u20138.","journal-title":"Oncologist"},{"issue":"2","key":"3126_CR11","doi-asserted-by":"publisher","first-page":"126","DOI":"10.3111\/13696998.2014.975233","volume":"18","author":"C-C Chuang","year":"2015","unstructured":"Chuang C-C, Bhurke S, Chen S-Y, Brulais S, Gabriel S. Clinical characteristics, treatment patterns, and economic burden in patients treated for neuroendocrine tumors in the United States: a retrospective cohort study. J Med Econ. 2015;18(2):126\u201336.","journal-title":"J Med Econ"},{"issue":"4","key":"3126_CR12","first-page":"188","volume":"12","author":"WP Glasheen","year":"2019","unstructured":"Glasheen WP, Cordier T, Gumpina R, et al. Charlson Comorbidity Index: ICD-9 update and ICD-10 translation. Am Health Drug Benefits. 2019;12(4):188\u201397.","journal-title":"Am Health Drug Benefits"},{"issue":"1","key":"3126_CR13","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/pds.3891","volume":"25","author":"International Society for Pharmacoepidemiology (ISoP) Public Policy Committee","year":"2016","unstructured":"International Society for Pharmacoepidemiology (ISoP) Public Policy Committee. Guidelines for good pharmacoepidemiology practice (GPP). Pharmacoepidemiol Drug Saf. 2016;25(1):2\u201310.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"3126_CR14","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1097\/EDE.0b013e3181577511","volume":"18","author":"JP Vandenbroucke","year":"2007","unstructured":"Vandenbroucke JP, von Elm E, Altman DG, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Epidemiology. 2007;18(6):805\u201335.","journal-title":"Epidemiology"},{"key":"3126_CR15","unstructured":"Guideline on good pharmacovigilance practices (GVP) module VI \u2013 collection, management and submission of reports of suspected adverse reactions to medicinal products (Rev 2). In: European Medicines Agency and Heads of Medicines Agencies London, England. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/guideline-good-pharmacovigilance-practices-gvp-module-vi-collection-management-and-submission-reports-suspected-adverse-reactions-medicinal-products-rev-2_en.pdf. Accessed 12 Apr 2024."},{"issue":"1","key":"3126_CR16","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1159\/000521288","volume":"91","author":"ME Charlson","year":"2022","unstructured":"Charlson ME, Carrozzino D, Guidi J, Patierno C. Charlson Comorbidity Index: a critical review of clinimetric properties. Psychother Psychosom. 2022;91(1):8\u201335.","journal-title":"Psychother Psychosom"},{"issue":"7","key":"3126_CR17","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1038\/bjc.2012.46","volume":"106","author":"TL J\u00f8rgensen","year":"2012","unstructured":"J\u00f8rgensen TL, Hallas J, Friis S, Herrstedt J. Comorbidity in elderly cancer patients in relation to overall and cancer-specific mortality. Br J Cancer. 2012;106(7):1353\u201360.","journal-title":"Br J Cancer"},{"issue":"8","key":"3126_CR18","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1634\/theoncologist.2018-0520","volume":"24","author":"A Dasari","year":"2019","unstructured":"Dasari A, Bergsland EK, Benson AB, et al. Treatment patterns and clinical outcomes in advanced lung neuroendocrine tumors in real-world settings: a multicenter retrospective chart review study. Oncologist. 2019;24(8):1066\u201375.","journal-title":"Oncologist"},{"issue":"10","key":"3126_CR19","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1634\/theoncologist.2018-0798","volume":"24","author":"AJ Klink","year":"2019","unstructured":"Klink AJ, Feinberg B, Yu HT, et al. Patterns of care among real-world patients with metastatic neuroendocrine tumors. Oncologist. 2019;24(10):1331\u20139.","journal-title":"Oncologist"},{"issue":"1","key":"3126_CR20","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13045-023-01510-9","volume":"16","author":"S Pusceddu","year":"2023","unstructured":"Pusceddu S, Corti F, Prinzi N, et al. Safety and antitumor activity of metformin plus lanreotide in patients with advanced gastro-intestinal or lung neuroendocrine tumors: the phase\u00a0Ib trial MetNET2. J Hematol Oncol. 2023;16(1):119.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"3126_CR21","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1053\/j.gastro.2018.04.010","volume":"155","author":"S Pusceddu","year":"2018","unstructured":"Pusceddu S, Vernieri C, Di Maio M, et al. Metformin use is associated with longer progression-free survival of patients with diabetes and pancreatic neuroendocrine tumors receiving everolimus and\/or somatostatin analogues. Gastroenterology. 2018;155(2):479-89.e7.","journal-title":"Gastroenterology"},{"issue":"1","key":"3126_CR22","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3390\/cancers14010069","volume":"14","author":"S Pusceddu","year":"2022","unstructured":"Pusceddu S, Vernieri C, Di Maio M, et al. Impact of diabetes and metformin use on enteropancreatic neuroendocrine tumors: post hoc analysis of the CLARINET Study. Cancers. 2022;14(1):69.","journal-title":"Cancers"},{"issue":"2","key":"3126_CR23","doi-asserted-by":"publisher","first-page":"R17","DOI":"10.1530\/JME-19-0083","volume":"63","author":"S Thakur","year":"2019","unstructured":"Thakur S, Daley B, Klubo-Gwiezdzinska J. The role of an anti-diabetic drug metformin in the treatment of endocrine tumors. J Mol Endocrinol. 2019;63(2):R17\u201335.","journal-title":"J Mol Endocrinol"},{"key":"3126_CR24","unstructured":"Amryt Pharma. Mycapssa (octreotide) [prescribing information]. US Food and Drug Administration."},{"key":"3126_CR25","unstructured":"COMP Adopts Positive Opinion on Orphan Designation for Mycapssa\u00ae for the Treatment of Carcinoid Syndrome Associated with Neuroendocrine Tumors [press release]. 19 December 2022."},{"key":"3126_CR26","unstructured":"Wyeth Pharmaceuticals. Protonix (pantoprazole sodium) [prescribing information]. US Food and Drug Administration."},{"issue":"7","key":"3126_CR27","first-page":"601","volume":"18","author":"C Palleria","year":"2013","unstructured":"Palleria C, Di Paolo A, Giofre C, et al. Pharmacokinetic drug-drug interaction and their implication in clinical management. J Res Med Sci. 2013;18(7):601\u201310.","journal-title":"J Res Med Sci"},{"issue":"6","key":"3126_CR28","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.sapharm.2015.11.001","volume":"12","author":"P Norris","year":"2016","unstructured":"Norris P, Tordoff J, McIntosh B, et al. Impact of prescription charges on people living in poverty: a qualitative study. Res Social Adm Pharm. 2016;12(6):893\u2013902.","journal-title":"Res Social Adm Pharm"},{"issue":"3","key":"3126_CR29","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.dld.2020.09.031","volume":"53","author":"S Massironi","year":"2021","unstructured":"Massironi S, Campana D, Pusceddu S, et al. Second primary neoplasms in patients with lung and gastroenteropancreatic neuroendocrine neoplasms: data from a retrospective multi-centric study. Dig Liver Dis. 2021;53(3):367\u201374.","journal-title":"Dig Liver Dis"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03126-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03126-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03126-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T06:50:57Z","timestamp":1744872657000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03126-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,13]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["3126"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03126-6","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"type":"print","value":"0741-238X"},{"type":"electronic","value":"1865-8652"}],"subject":[],"published":{"date-parts":[[2025,3,13]]},"assertion":[{"value":"25 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jennifer Chan: receipt of grants\/research supports: Lilly, Sanofi; receipt of honoraria or consultation fees: Novartis\/Advanced Accelerator Applications, Curium, Ipsen, Lantheus; stock shareholder: Merck.. Antonio Ribeiro-Oliveira\u00a0Jr.: employee: was a shareholder and an Ipsen employee at the time of manuscript development.. Aude Houchard and Christelle Pommie: shareholder and employee: Ipsen. Syvart Dennen: employee: Genesis Research Group, which received consultation fees from Ipsen. Yutong Liu: employee: Genesis Research Group, which received consultation fees from Ipsen. Sai Sriteja Boppudi Naga: employee: Genesis Research Group, which received consultation fees from Ipsen. Yajin Zhao: employee: Genesis Research Group, which received consultation fees from Ipsen. Timon Vandamme: reports consultancy, advisory roles, honoraria from AstraZeneca, Astellas, Bayer, Bristol Myers Squibb, Eisai, Elmedix, Ipsen, MyNeoTx, Nordic Pharma, Novartis, Roche, Sirtex, Servier, Takeda. Research funding (institutional) from Ipsen and Novartis. Support for travel\/accomodation from Ipsen, AstraZeneca and Servier.. Jason Starr: receipt of grants\/research supports (institution): Amgen, Aminex Therapeutics, Aprea Therapeutics, Arcus Biosciences, Camurus AB, Cardiff, Leap Therapeutics, Rayze Bio; receipt of honoraria or consultation: Advanced Accelerator Applications, Ipsen, Natera, Tempus Tersera; other support: travel (Camurus).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was designed and implemented and reported in accordance with the Guidelines for Good Pharmacoepidemiology Practices (GPP) of the International Society for Pharmacoepidemiology (ISPE 2016) [], the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) guidelines [], and the ethical principles laid down in the Declaration of Helsinki [].","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}